Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study

BACKGROUND: Denosumab inhibits the receptor activator of nuclear factor κB (RANK) pathway and is used to treat osteoporosis. Emerging evidence suggests RANK-blockade may play a role in mammary tumourigenesis. Thus, we undertook a population-based study of denosumab use and breast cancer risk in a la...

Descripción completa

Detalles Bibliográficos
Autores principales: Giannakeas, Vasily, Cadarette, Suzanne M., Ban, Joann K., Lipscombe, Lorraine, Narod, Steven A., Kotsopoulos, Joanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6265331/
https://www.ncbi.nlm.nih.gov/pubmed/30420611
http://dx.doi.org/10.1038/s41416-018-0225-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6265331/
https://www.ncbi.nlm.nih.gov/pubmed/30420611
http://dx.doi.org/10.1038/s41416-018-0225-4

Ejemplares similares